|
06 Mar 2019 |
AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes
|
|
06 Mar 2019 |
Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
|
|
06 Mar 2019 |
Iksuda Therapeutics and Femtogenix sign license agreement
|
|
05 Mar 2019 |
Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016
|
|
05 Mar 2019 |
Xenetic Biosciences, Inc. Announces Agreement to Acquire Innovative CAR T Technology Platform
|
|
04 Mar 2019 |
Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation
|
|
04 Mar 2019 |
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
|
|
04 Mar 2019 |
Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
|
|
02 Mar 2019 |
AdoRx Therapeutics Announces Collaboration With Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics
|
|
02 Mar 2019 |
MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company
|
|
28 Feb 2019 |
Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies
|
|
28 Feb 2019 |
Sarepta Exercises Option to Acquire Myonexus Therapeutics
|
|
27 Feb 2019 |
Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics for Pain
|
|
27 Feb 2019 |
Selexis SA and Turgut Pharmaceuticals Expand Biosimilar Development Relationship by Signing Two Commercial License Agreements
|
|
27 Feb 2019 |
Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
|
|
26 Feb 2019 |
Immunotherapy Company TC BioPharm Partners with Trinity College Dublin to Develop V Delta 1 γδ T Cell-based Cancer Treatments
|
|
26 Feb 2019 |
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
|
|
25 Feb 2019 |
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
|
|
25 Feb 2019 |
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
|
|
25 Feb 2019 |
Roche enters into definitive merger agreement to acquire Spark Therapeutics
|
|
24 Feb 2019 |
Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration
|
|
24 Feb 2019 |
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
|
|
21 Feb 2019 |
Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
|
|
21 Feb 2019 |
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
|
|
21 Feb 2019 |
Merck to Acquire Immune Design
|
